The technological advancement in the field of cancer biology has led to identification of CD47 as next generation therapeutic target.
Global CD47 Inhibitor Drug Clinical Trials Insight 2028 Report Highlights:
- CD47 Inhibitor Drug Market Trends & Future Prospects
- Insight On More Than 50 CD47 Inhibitors Drugs In Clinical Trials
- Orphan, Fast Track, Breakthrough Therapy Designation Insight
- Insight On CD47 Inhibitors Drugs Biomarkers Sourced During Clinical Trials
- CD47 Inhibitors Drug Clinical Trials Insight By Company, Indication & Phase
- CD47 Inhibitors Drug Clinical Trials Insight As Mono & Combination Therapy
- Global CD47 Inhibitor Drug Market Dynamics
Download Report Sample: https://www.kuickresearch.com/report-cd47-inhibitor-drugs-clinical-trials
The technological advancement in the field of cancer biology has led to identification of CD47 as next generation therapeutic target. CD47 or integrin-associated protein (IAP) is trans-membrane glycoprotein widely expressed on normal cells and it functions mainly as a marker for macrophages to differentiate “self” from “non-self”. Apart from this, the overexpression of CD47 is also associated with several cancers such as ovarian cancer, acute myeloid leukemia, breast cancer, Hodgkin lymphoma, myeloma, and others. Further, CD47 signaling pathway is also critical for the progression of cancer. Owing to these characteristics, CD47 as therapeutic target has gained significant interest from pharmaceutical companies worldwide.
Currently, CD47 targeting therapies development is confined to preclinical and clinical stages. Keeping in mind the huge clinical success of monoclonal antibodies, researchers have developed CD47 targeting monoclonal antibodies. Several potential CD47 monoclonal antibodies have been developed including as Magrolimab, AK117, TQB2928, ZL-1201, Letaplimab, STI-6643, IMC-002, and others. Ongoing clinical trials are evaluating the role of monoclonal antibodies as monotherapy or combination therapy in wide range of solid tumors as well as hematological malignancies. For instance, AK117 developed by Akeso is being evaluated in phase-I/II trial as monotherapy or in combination with azacitidine or pacilataxel for the management of solid tumors.
Further, the progress in antibody engineering has led to development of dual targeting antibodies, or bispecific antibodies which have the ability to target two different antigens simultaneously. Currently, only few bispecific antibody constructs have been developed including PF-07257876, HX009, BAT7104, IB1322, and IMM0306 which are rapidly demonstrating encouraging data. For instance, Innovent Biologics recently announced the encouraging results of phase-I trial of IB1322 (anti-CD47 /PD-L1 bispecific antibody). The company reported that the investigational bispecific antibody construct has shown favorable safety and tolerability profile in patients with advanced solid tumors. Further trials are being initiated to further explore the safety and efficacy of IB1322 in multiple oncological conditions.
The global CD47 inhibitor market is highly competitive with wide range of pharmaceutical companies actively investing in research and development activities related to this segment. The key players in the market have also adopted strategic alliances such as collaboration, partnership, acquisitions, or joint ventures to maintain their position in the global market. For instance in 2022, Actinium Pharmaceuticals entered into research collaboration with EpicentRx to study Actinium's Actimab-A targeted radiotherapy in combination with RRx-001, EpicentRx's novel small molecule immunotherapy targeting the CD47-SIRPα axis. The companies will initiate clinical trial evaluating the role of novel combination in patients with acute myeloid leukemia.
Although US is one of the major region favoring the research and development activities related to CD47 targeting therapies, much progress for CD47 inhibitors has also been witness in China. To date, more than 17 drugs have been approved for clinical research by NMPA which accounts for almost half of the clinical pipeline products globally. The domestic Chinese pharmaceutical companies including I-Mab BioPharma, Innovent Biologics, ImmuneOnco, Hengrui, Waterstone Hanxbio, and others have developed a robust pipeline of CD47 targeting agents which are expected to gain approval in near future.
As per our report findings, the global CD47 inhibitor market will surpass US$ 2 Billion by 2028. The huge growth rates in the forecast period which is attributed to several factors such as increase in research and development activities by pharmaceutical companies, surge in prevalence of cancer and associated demand for the targeted therapy, and favorable government initiatives. It is expected that CD47 inhibitors will hold a significant share in the global cancer immunotherapy market in near future.
Contact:
Neeraj Chawla
Kuick Research
Research Head
+91-9810410366